Unlocking potential to create new possibilities
We are deeply saddened by the death of Her Majesty Queen, Elizabeth II. The world has lost an inspirational and wise leader who had a profound sense of duty. We send our heartfelt condolences to the Royal Family.
Mereo BioPharma Group today reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors. These biomarker data were presented at a poster session at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting on September 10, 2022.
Mereo BioPharma and Ultragenyx to Present Setrusumab Data Update at ASBMR09 September 2022
Mereo BioPharma and Ultragenyx Pharmaceutical Inc. today announced that additional data relevant to setrusumab will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR) being held September 9-12, 2022, in Austin, Texas.
Mereo BioPharma Group plc today sent a letter to Rubric Capital Management LP (“Rubric”) responding to Rubric’s recent public statements regarding Mereo’s business and the opportunity for value creation from its pipeline, as well as Rubric’s proposed slate of directors. Mereo also reiterated its updated strategy and capital allocation plan, which it believes will maximize value for all shareholders.
Mereo BioPharma Sends Letter to Rubric Capital Management22 August 2022
Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on rare diseases and oncology, today sent a letter to Rubric Capital Management LP (“Rubric”) responding to a letter from Rubric dated August 19, 2022.